Patient Access Support for Healthcare Professionals
The Helsinn Cares program is designed to provide support and resources for AKYNZEO® reimbursement—and to allow you and your office staff to focus on patient care.
Start the process by enrolling your patients in Helsinn Cares today!
When you enroll your patients in Helsinn Cares, the program can help with confirming benefit coverage and facilitate prior authorizations or appeals, when required. And, if your patient meets eligibility criteria, then he or she will be considered for the Patient Assistance Program.
AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1
Important Safety Information
Warnings and Precautions
Use in Specific Populations
For more information about AKYNZEO, please see Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1-855-541-3498 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
1. AKYNZEO® (netupitant/palonosetron) capsules. Full Prescribing Information.
AKYNZEO® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.